Top-quality, rapidly growing European stocks are selling at enticing valuations
Timothy Lewis, portfolio manager at JPMorgan European Growth & Income tells us where he’d put his money
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
The JPMorgan European Growth & Income trust seeks to invest in quality businesses at attractive valuations. By this, we mean well-run companies that produce strong and sustainable returns on invested capital, where earnings per share translate to tangible cash flow, and also those with management teams making sensible decisions with their capital.
One of the most important attributes we look for in companies is improving operational momentum. One way to assess this is by tracking management guidance and earnings-per-share expectations to see whether they are being upgraded or downgraded over time.
In this regard, Europe provides a rich opportunity, thanks to extreme valuation discounts relative to US peers, the much-improved quality of the firms in our index and the strengthening macroeconomic backdrop. Below are three long-standing holdings in the trust, firms that have displayed strong operating momentum for some time and should be able to continue that performance in the future.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A monumental medical leap forward
Novo Nordisk (Copenhagen: NOVO-B) is unique in the pharmaceuticals sector in that it has been almost completely focused on insulin and diabetes for more than a hundred years. It has leveraged its strength in diabetes care into a leading position in the interrelated issue of obesity. Obesity has posed significant challenges for medical practitioners worldwide. Despite advances in healthcare, effective treatment options for obesity have been limited, often culminating in surgical interventions as a last resort.
However, the introduction of Novo Nordisk’s pioneering new drug Wegovy represents a monumental leap forward in the realm of weight-loss treatments. With efficacy levels comparable to surgical procedures, but with significantly reduced risks, Wegovy has emerged as a game-changer in the fight against obesity. Patients’ interest in this revolutionary new drug has continued to exceed expectations, leading to strong operating momentum for the business, but with a market opportunity that can justify sustained growth.
As interest rates have normalised over the past few years, Italy’s UniCredit (Milan: UCG) has experienced an expansion in net-interest margins. This uptrend has resulted in frequent upgrades to earnings forecasts, supporting the sector’s robust performance amid changing market conditions. But valuations for banks such as UniCredit remain compelling, offering an attractive entry point for investors.
Furthermore, thanks to strong capital positions, banks are able to return cash to shareholders through dividends and share buybacks. This shareholder-friendly approach underscores UniCredit’s commitment to delivering long-term value and solidifies its position as an enticing opportunity within the banking sector.
Pioneering Publicis
Ten years ago, Publicis (Paris: PUB) began a journey to lead the advertising industry in data and technology, which included two large acquisitions, Epsilon and Sapient. That journey hasn’t been without bumps in the road, with Covid, a challenging macro-environment and the integration of these two acquisitions to navigate.
However, Publicis is now in a stronger position and has emerged into a much more supportive economic backdrop. It has elevated itself into a “transformation partner” that is data-driven and puts technology first, and which is better able to meet clients’ needs and win market share. Publicis is now the standout leader in the field and looks set to continue that growth.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Tim Lewis, Executive Director, is a portfolio manager within the J.P. Morgan Asset Management International Equity Group, based in London. He has a particular focus on core Europe mandates. An employee since 2013, Tim joined the firm as a graduate trainee. He obtained a BA in Business and Economics at Trinity College Dublin, and an MSc in Behavioural Economics from the University of Nottingham and is a CFA charterholder.
-
Should you buy an active ETF?ETFs are often mischaracterised as passive products, but they can be a convenient way to add active management to your portfolio
-
Power up your pension before 5 April – easy ways to save before the tax year endWith the end of the tax year looming, pension savers currently have a window to review and maximise what’s going into their retirement funds – we look at how
-
Three key winners from the AI boom and beyondJames Harries of the Trojan Global Income Fund picks three promising stocks that transcend the hype of the AI boom
-
RTX Corporation is a strong player in a growth marketRTX Corporation’s order backlog means investors can look forward to years of rising profits
-
Profit from MSCI – the backbone of financeAs an index provider, MSCI is a key part of the global financial system. Its shares look cheap
-
'AI is the real deal – it will change our world in more ways than we can imagine'Interview Rob Arnott of Research Affiliates talks to Andrew Van Sickle about the AI bubble, the impact of tariffs on inflation and the outlook for gold and China
-
Should investors join the rush for venture-capital trusts?Opinion Investors hoping to buy into venture-capital trusts before the end of the tax year may need to move quickly, says David Prosser
-
Food and drinks giants seek an image makeover – here's what they're doingThe global food and drink industry is having to change pace to retain its famous appeal for defensive investors. Who will be the winners?
-
Barings Emerging Europe trust bounces back from Russia woesBarings Emerging Europe trust has added the Middle East and Africa to its mandate, delivering a strong recovery, says Max King
-
How a dovish Federal Reserve could affect youTrump’s pick for the US Federal Reserve is not so much of a yes-man as his rival, but interest rates will still come down quickly, says Cris Sholto Heaton
